Status:

COMPLETED

Comparing Pulmonary Vein Isolation to Pulmonary Vein Isolation + OPTIMA Ablation in Patients Undergoing Ablation for Atrial Fibrillation

Lead Sponsor:

Johns Hopkins University

Collaborating Sponsors:

National Heart, Lung, and Blood Institute (NHLBI)

Conditions:

Atrial Fibrillation Chronic

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Catheter ablation is an established cornerstone of therapy for patients with symptomatic atrial fibrillation (AF) who wish to avoid anti-arrhythmic drug therapy or for whom anti-arrhythmics have prove...

Detailed Description

Background: Atrial fibrillation (AF) is the most commonly encountered clinical arrhythmia. Symptoms arising from AF are common, and may include palpitations, fatigue, exertional intolerance, and angin...

Eligibility Criteria

Inclusion

  • Eligible patients must be at least 18 years old at the time of enrollment.
  • Patient was referred to Johns Hopkins cardiac electrophysiology division for clinically indicated catheter ablation for persistent or long standing persistent AF either for index ablation or redo ablation.
  • Patient is currently on systemic anticoagulation or has no contraindication to initiate systemic anticoagulation.
  • Capable of undergoing informed consent.
  • A Pre-Op cardiac MRI including LGE in sinus rhythm must be performed prior to ablation and patient should be capable of undergoing cardioversion and cardiac MRI.
  • MRI scan should show evidence of left atrial scarring.

Exclusion

  • Patient is not a suitable candidate for AF ablation.
  • Patient is currently not on anticoagulation and has significant contraindications to initiate systemic anticoagulation.
  • Pregnant women may not participate in the study because gadolinium MRI contrast is contraindicated in pregnancy.
  • Patient with Body weight more than 300 lbs as they cannot undergo MRI scans.
  • Patients with Glomerular Filtration Rate (GFR) \< 30 mL/min should not be enrolled in the study due to the use of intravenous gadolinium as an MRI contrast agent.
  • No evidence of Left Arial fibrosis in MRI scan as these images are not suitable for simulation.
  • Inability to get MRI in sinus rhythm.
  • Long standing persistent AF more than 3 years of duration.
  • Prior surgical maze procedure.

Key Trial Info

Start Date :

September 1 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2025

Estimated Enrollment :

67 Patients enrolled

Trial Details

Trial ID

NCT04101539

Start Date

September 1 2019

End Date

October 1 2025

Last Update

October 9 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Johns Hopkins Hospital

Baltimore, Maryland, United States, 21287

Comparing Pulmonary Vein Isolation to Pulmonary Vein Isolation + OPTIMA Ablation in Patients Undergoing Ablation for Atrial Fibrillation | DecenTrialz